193 related articles for article (PubMed ID: 36894968)
1. Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey.
Brothers S; Palayew A; Simon C; Coulter A; Strichartz K; Voyles N; Vincent L
Harm Reduct J; 2023 Mar; 20(1):31. PubMed ID: 36894968
[TBL] [Abstract][Full Text] [Related]
2. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
3. Take-home dosing experiences among persons receiving methadone maintenance treatment during COVID-19.
Figgatt MC; Salazar Z; Day E; Vincent L; Dasgupta N
J Subst Abuse Treat; 2021 Apr; 123():108276. PubMed ID: 33612201
[TBL] [Abstract][Full Text] [Related]
4. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
[TBL] [Abstract][Full Text] [Related]
5. Loss, liberation, and agency: Patient experiences of methadone treatment at opioid treatment programs during the COVID-19 pandemic.
López-Castro T; Jakubowski A; Masyukova M; Peterson M; Pierz A; Kodali S; Arnsten JH; Starrels JL; Nahvi S
J Subst Use Addict Treat; 2024 Feb; 157():209235. PubMed ID: 38061636
[TBL] [Abstract][Full Text] [Related]
6. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
7. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
Meyerson BE; Bentele KG; Russell DM; Brady BR; Downer M; Garcia RC; Garnett I; Lutz R; Mahoney A; Samorano S; Arredondo C; Andres HJ; Coles H; Granillo B
PLoS One; 2022; 17(10):e0274094. PubMed ID: 36282806
[TBL] [Abstract][Full Text] [Related]
8. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
Roy V; Buonora M; Simon C; Dooling B; Joudrey P
Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
[TBL] [Abstract][Full Text] [Related]
9. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
[No Abstract] [Full Text] [Related]
10. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
[No Abstract] [Full Text] [Related]
11. Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: results from a feasibility clinical trial.
Wu LT; John WS; Morse ED; Adkins S; Pippin J; Brooner RK; Schwartz RP
Addiction; 2022 Feb; 117(2):444-456. PubMed ID: 34286886
[TBL] [Abstract][Full Text] [Related]
12. Experiences with substance use disorder treatment during the COVID-19 pandemic: Findings from a multistate survey.
Saloner B; Krawczyk N; Solomon K; Allen ST; Morris M; Haney K; Sherman SG
Int J Drug Policy; 2022 Mar; 101():103537. PubMed ID: 34871945
[TBL] [Abstract][Full Text] [Related]
13. "It's like 'liquid handcuffs": The effects of take-home dosing policies on Methadone Maintenance Treatment (MMT) patients' lives.
Frank D; Mateu-Gelabert P; Perlman DC; Walters SM; Curran L; Guarino H
Harm Reduct J; 2021 Aug; 18(1):88. PubMed ID: 34391436
[TBL] [Abstract][Full Text] [Related]
14. Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS).
Smith LR; Mittal ML; Wagner K; Copenhaver MM; Cunningham CO; Earnshaw VA
Addiction; 2020 Feb; 115(2):354-367. PubMed ID: 31478272
[TBL] [Abstract][Full Text] [Related]
15. Technology-assisted methadone take-home dosing for dispensing methadone to persons with opioid use disorder during the Covid-19 pandemic.
Dunn KE; Brooner RK; Stoller KB
J Subst Abuse Treat; 2021 Feb; 121():108197. PubMed ID: 33357606
[TBL] [Abstract][Full Text] [Related]
16. The impact of relaxation of methadone take-home protocols on treatment outcomes in the COVID-19 era.
Amram O; Amiri S; Panwala V; Lutz R; Joudrey PJ; Socias E
Am J Drug Alcohol Abuse; 2021 Nov; 47(6):722-729. PubMed ID: 34670453
[TBL] [Abstract][Full Text] [Related]
17. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
[TBL] [Abstract][Full Text] [Related]
18. Experience of patients on methadone maintenance treatment receiving take-home methadone doses during COVID-19 pandemic: A multi-site study from India.
Kathiresan P; Patel V; Jangra J; Chattopadhyay A; Abdus S; Jadhav M; Rao R; Arya A; Bansal PD; Chinggouman C; Bhad R; Ambekar A; Agrawal A; Chatterjee B; Yadav D
Asian J Psychiatr; 2024 May; 95():103979. PubMed ID: 38442535
[TBL] [Abstract][Full Text] [Related]
19. Association Between Increased Dispensing of Opioid Agonist Therapy Take-Home Doses and Opioid Overdose and Treatment Interruption and Discontinuation.
Gomes T; Campbell TJ; Kitchen SA; Garg R; Bozinoff N; Men S; Tadrous M; Munro C; Antoniou T; Werb D; Wyman J
JAMA; 2022 Mar; 327(9):846-855. PubMed ID: 35230394
[TBL] [Abstract][Full Text] [Related]
20. Improved treatment-retention for patients receiving methadone dosing within the clinic providing physician and other health services (onsite) versus dosing at community (offsite) pharmacies.
Gauthier G; Eibl JK; Marsh DC
Drug Alcohol Depend; 2018 Oct; 191():1-5. PubMed ID: 30064001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
